Should I buy or sell Penumbra stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PEN shares. View PEN analyst ratings or view top-rated stocks .

What is Penumbra's stock price target for 2024?

12 Wall Street research analysts have issued 12 month target prices for Penumbra's shares. Their PEN share price targets range from $240.00 to $376.00. On average, they expect the company's share price to reach $317.25 in the next twelve months. This suggests a possible upside of 41.6% from the stock's current price. View analysts price targets for PEN or view top-rated stocks among Wall Street analysts .

How have PEN shares performed in 2023?

Penumbra's stock was trading at $222.46 on January 1st, 2023. Since then, PEN shares have increased by 0.7% and is now trading at $224.04. View the best growth stocks for 2023 here .

When is Penumbra's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our PEN earnings forecast .

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) released its earnings results on Thursday, November, 2nd. The company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.46 by $0.21. The firm earned $270.95 million during the quarter, compared to the consensus estimate of $266.02 million. Penumbra had a net margin of 4.08% and a trailing twelve-month return on equity of 5.54%.

What ETFs hold Penumbra's stock?

ETFs with the largest weight of Penumbra (NYSE:PEN) stock in their portfolio include Fidelity Disruptive Medicine ETF (FMED) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , MFAM Small-Cap Growth ETF (MFMS) , Motley Fool Small-Cap Growth ETF (TMFS) , First Trust Indxx Medical Devices ETF (MDEV) , Alpha Architect U.S. Quantitative Momentum ETF (QMOM) , First Trust Health Care AlphaDEX Fund (FXH) and SPDR S&P Health Care Equipment ETF (XHE) .

What is Adam Elsesser's approval rating as Penumbra's CEO?

57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com . Adam Elsesser has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA) , Intuitive Surgical (ISRG) , AbbVie (ABBV) , Tesla (TSLA) , Alibaba Group (BABA) , Johnson & Johnson (JNJ) , Netflix (NFLX) , UnitedHealth Group (UNH) , Boeing (BA) and DexCom (DXCM) .

Who are Penumbra's major shareholders?

Penumbra's stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (13.00%), Clearbridge Investments LLC (2.35%), Baillie Gifford & Co. (1.76%), William Blair Investment Management LLC (1.70%), Invesco Ltd. (1.43%) and Rock Springs Capital Management LP (1.31%). Insiders that own company stock include Adam Elsesser , Arani Bose , Bridget O'rourke , Don W Kassing, Harpreet Grewal , James Robert Pray , Johanna Roberts , Surbhi Sarna and Thomas Wilder . View institutional ownership trends .

How do I buy shares of Penumbra?

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Penumbra Stock Price, News & Analysis (NYSE:PEN)

$224.04

+0.85 (+0.38%)

(As of 12/8/2023 ET)

Compare

Today's Range: $221.14
▼
$224.73
50-Day Range: $181.44
▼
$238.35
52-Week Range: $180.93
▼
$348.67

Volume: 279,165 shs
Average Volume: 442,441 shs
Market Capitalization: $8.65 billion

P/E Ratio: 217.52
Dividend Yield: N/A
Price Target: $317.25

Penumbra MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 41.6% Upside
$317.25 Price Target
Short Interest: Bearish
6.48% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.33
Upright™ Environmental Score
News Sentiment: 0.72
Based on 7 Articles This Week
Insider Trading: Selling Shares
$5.46 M Sold Last Quarter
Proj. Earnings Growth: 42.16%
From $2.04 to $2.90 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

164th out of 932 stocks

Surgical & Medical Instruments Industry

26th out of 93 stocks

3.4

Analyst's Opinion

Consensus Rating
Penumbra has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $317.25, Penumbra has a forecasted upside of 41.6% from its current price of $224.04.
Amount of Analyst Coverage
Penumbra has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.48% of the outstanding shares of Penumbra have been sold short.
Short Interest Ratio / Days to Cover
Penumbra has a short interest ratio ("days to cover") of 5.9.
Change versus previous month
Short interest in Penumbra has recently increased by 4.60%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Penumbra does not currently pay a dividend.
Dividend Growth
Penumbra does not have a long track record of dividend growth.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Penumbra has received a 46.04% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Surgical instruments" product. See details.
Environmental Sustainability
The Environmental Impact score for Penumbra is -1.33.

3.2

News and Social Media Coverage

News Sentiment
Penumbra has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Penumbra this week, compared to 5 articles on an average week.
Search Interest
Only 7 people have searched for PEN on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.
MarketBeat Follows
3 people have added Penumbra to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Penumbra insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,456,171.00 in company stock.
Percentage Held by Insiders
Only 5.30% of the stock of Penumbra is held by insiders.
Percentage Held by Institutions
88.18% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Penumbra are expected to grow by 42.16% in the coming year, from $2.04 to $2.90 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Penumbra is 217.52, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 110.24.
Price to Earnings Ratio vs. Sector
The P/E ratio of Penumbra is 217.52, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 107.63.
Price to Book Value per Share Ratio
Penumbra has a P/B Ratio of 8.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Penumbra Stock (NYSE:PEN)

Penumbra, Inc., together with its subsidiairies, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, SENDit, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System, Lightning, and CAT RX brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and POD (Penumbra Occlusion Device) brand, as well as immersive 3D computer-based technology platform under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

PEN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PEN Stock News Headlines

December 9, 2023 | americanbankingnews.com

Analyzing BrainsWay (NASDAQ:BWAY) & Penumbra (NYSE:PEN)

November 30, 2023 | finance.yahoo.com

Wall Street Analysts See a 26.89% Upside in Penumbra (PEN): Can the Stock Really Move This High?

December 10, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 30, 2023 | msn.com

Penumbra (PEN) Enrolls First Patient in Landmark STORM-PE Trial

November 29, 2023 | msn.com

Penumbra enrols first patient in trial of Lightning Flash

November 28, 2023 | finance.yahoo.com

First Patient in STORM-PE RCT Enrolled Evaluating Penumbra's Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash™ - for Treatment of Acute Pulmonary Embolism

November 17, 2023 | finance.yahoo.com

Insider Sell Alert: EVP Johanna Roberts Sells Shares of Penumbra Inc

November 14, 2023 | finance.yahoo.com

Penumbra, Inc. to Present at the Piper Sandler 35th Annual Healthcare Conference

December 10, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 14, 2023 | finance.yahoo.com

Wall Street Analysts Think Penumbra (PEN) Could Surge 37.71%: Read This Before Placing a Bet

November 13, 2023 | msn.com

Penumbra, Verve Therapeutics among healthcare movers

November 13, 2023 | barrons.com

S&P 500 Futures Decline in Premarket Trading; monday.com, Penumbra Lead

November 10, 2023 | finance.yahoo.com

Penumbra Teams Up with Honor Everywhere to Bring US War Memorials to Aging Veterans

November 9, 2023 | msn.com

Down -11.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Penumbra (PEN)

November 3, 2023 | finance.yahoo.com

Penumbra touts benefits of vacuum thrombectomy for PE in late-breaking data

November 3, 2023 | finance.yahoo.com

Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase

November 3, 2023 | finance.yahoo.com

Penumbra, Inc. (NYSE:PEN) Q3 2023 Earnings Call Transcript

November 3, 2023 | msn.com

Penumbra GAAP EPS of $0.23

November 2, 2023 | sfgate.com

Penumbra: Q3 Earnings Snapshot

November 2, 2023 | finance.yahoo.com

Penumbra, Inc. Reports Third Quarter 2023 Financial Results

November 2, 2023 | finance.yahoo.com

Penumbra Inc (PEN) Reports 26.8% Revenue Increase in Q3 2023

November 1, 2023 | markets.businessinsider.com

Here's what Wall Street expects from Penumbra's earnings report

November 1, 2023 | finance.yahoo.com

NEW LATE BREAKING DATA DEMONSTRATE PENUMBRA'S COMPUTER ASSISTED VACUUM THROMBECTOMY TECHNOLOGY FOR PULMONARY EMBOLISM IMPROVED PATIENT OUTCOMES

October 27, 2023 | finance.yahoo.com

Penumbra (PEN) Declined on Weak Second Quarter Earnings

October 24, 2023 | finance.yahoo.com

Penumbra (PEN) to Report Q3 Earnings: What's in the Cards?

October 20, 2023 | msn.com

Partial lunar eclipse: Will it be visible in India?

October 16, 2023 | msn.com

Penumbra: Appeal Improves, Just Not Appealing Yet

See More Headlines

Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/10/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/22/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:PEN
CUSIP: N/A
CIK: 1321732
Web: www.penumbrainc.com
Phone: (510) 748-3200
Fax: 510-748-3232
Employees: 3,900
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $317.25
High Stock Price Target: $376.00
Low Stock Price Target: $240.00
Potential Upside/Downside: +41.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.03
Trailing P/E Ratio: 217.52
Forward P/E Ratio: 109.82
P/E Growth: N/A
Net Income: $-2,000,000.00
Net Margins: 4.08%
Pretax Margin: 4.89%
Return on Equity: 5.54%
Return on Assets: 4.10%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 5.99
Quick Ratio: 3.41

Sales & Book Value

Annual Sales: $847.13 million
Price / Sales: 10.21
Cash Flow: $0.81 per share
Price / Cash Flow: 276.08
Book Value: $26.30 per share
Price / Book: 8.52

Miscellaneous

Outstanding Shares: 38,600,000
Free Float: 36,550,000
Market Cap: $8.65 billion
Optionable: Optionable
Beta: 0.62

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Adam Elsesser (Age 61)
Co-Founder, Chairman, President & CEO
Comp: $601.62k
Dr. Arani Bose M.D. (Age 61)
Co-Founder & Director
Comp: $37.5k
Ms. Maggie S. Yuen (Age 51)
Chief Financial Officer
Comp: $660.98k
Mr. Lambert Shiu (Age 43)
Chief Accounting Officer
Comp: $539.15k
Ms. Johanna Roberts (Age 51)
Executive VP, General Counsel & Secretary
Comp: $655.75k
Mr. Ben Sorci
Executive Vice President of Operations
Mr. Pankaj Tiwari
Executive VP & Chief Information Officer
Ms. Jee Hamlyn-Harris
Investor Relations Officer
Mr. Ben Tompkins
Executive Vice President of Development
Ms. Gita Barry
President of Immersive Healthcare

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Penumbra stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PEN shares.
View PEN analyst ratings or view top-rated stocks.
What is Penumbra's stock price target for 2024?: 12 Wall Street research analysts have issued 12 month target prices for Penumbra's shares. Their PEN share price targets range from $240.00 to $376.00. On average, they expect the company's share price to reach $317.25 in the next twelve months. This suggests a possible upside of 41.6% from the stock's current price.
View analysts price targets for PEN or view top-rated stocks among Wall Street analysts.
How have PEN shares performed in 2023?: Penumbra's stock was trading at $222.46 on January 1st, 2023. Since then, PEN shares have increased by 0.7% and is now trading at $224.04.
View the best growth stocks for 2023 here.
When is Penumbra's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our PEN earnings forecast.
How were Penumbra's earnings last quarter?: Penumbra, Inc. (NYSE:PEN) released its earnings results on Thursday, November, 2nd. The company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.46 by $0.21. The firm earned $270.95 million during the quarter, compared to the consensus estimate of $266.02 million. Penumbra had a net margin of 4.08% and a trailing twelve-month return on equity of 5.54%.
What ETFs hold Penumbra's stock?: ETFs with the largest weight of Penumbra (NYSE:PEN) stock in their portfolio include Fidelity Disruptive Medicine ETF (FMED), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), First Trust Indxx Medical Devices ETF (MDEV), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), First Trust Health Care AlphaDEX Fund (FXH) and SPDR S&P Health Care Equipment ETF (XHE).

What is Adam Elsesser's approval rating as Penumbra's CEO?: 57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees.
What other stocks do shareholders of Penumbra own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM).
Who are Penumbra's major shareholders?: Penumbra's stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (13.00%), Clearbridge Investments LLC (2.35%), Baillie Gifford & Co. (1.76%), William Blair Investment Management LLC (1.70%), Invesco Ltd. (1.43%) and Rock Springs Capital Management LP (1.31%). Insiders that own company stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Surbhi Sarna and Thomas Wilder.
View institutional ownership trends.
How do I buy shares of Penumbra?: Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:PEN) was last updated on 12/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Penumbra Stock Price, News & Analysis (NYSE:PEN)

Penumbra MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Penumbra Stock (NYSE:PEN)

PEN Stock Price History

PEN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PEN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™